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ABSTRACT
Background: Medication-related problems often occur in the
immediate post-discharge period. To reduce medication
misadventure the Commonwealth Government funds home
medicines reviews (HMRs). HMRs are initiated when general
practitioners refer consenting patients to their community
pharmacists, who then engage accredited pharmacists to review
patients’ medicines in their homes.
Aim: To determine if hospital-initiated medication reviews
(HIMRs) can be implemented in a more timely manner than
HMRs; and to assess the impact of a bespoke referral form
with comorbidity-specific questions on the quality of reports.
Method: Eligible medical inpatients at risk of medication
misadventure were referred by the hospital liaison pharmacist
to participating accredited pharmacists post-discharge from
hospital. Social, demographic and laboratory data were collected
from medical records and during interviews with consenting
patients. Issues raised in the HIMR reports were categorised:
intervention/action, information given or recommendation, and
assigned a rank of clinical significance.
Results: HIMRs were conducted within 11.6 ± 6.6 days post-
discharge. 36 HIMR reports were evaluated and 1442 issues
identified – information given (n = 1204), recommendations
made (n = 88) and actions taken (n = 150). The majority of
issues raised (89%) had a minor clinical impact. The bespoke
referral form prompted approximately half of the issues raised.
Conclusion: HIMRs can be facilitated in a more timely manner
than post-discharge HMRs. There was an associated positive
clinical impact of issues raised in the HIMR reports.
J Pharm Pract Res 2009; 39: 269-73.
INTRODUCTION
Medication misadventures can occur in the immediate
post-discharge period with associated morbidity and cost
burden.1 Risk factors for medication misadventure include
being elderly, living alone, polypharmacy, multiple
comorbidities, cultural and language barriers, cognitive
impairment, suboptimal transfer of current medication
lists between episodes of care and inadequate consumer
education.2,3 Numerous strategies have been proposed
to improve medication management: optimising
medication regimens and providing written and verbal
information.3-11 When home medicines reviews (HMRs)
are conducted in the immediate post-discharge period
they provide an opportunity to implement these strategies
at a critical time in the transition from hospital to home.6
Home Medicines Review
The Australian HMR program introduced in 2001 aims to
increase consumers’ understanding of their medicines,
reduce the occurrence of medication-related problems
and encourage general practitioners (GPs) and
pharmacists to work collaboratively to optimise
medication management.12-14 HMRs are initiated when GPs
refer consenting patients to their community pharmacists,
who engage accredited pharmacists to review patients’
medicines in their homes. The accredited pharmacists
send reports to the GP and community pharmacist.6
To achieve quality use of medicines, effective
communication is needed between hospital and
community practitioners.11 The Australian Pharmaceutical
Advisory Council’s guiding principles address the
discontinuity of care that results from suboptimal
discharge processes with respect to communication of
medicines information.11
HMRs organised for patients post-discharge can
improve the transfer of medicines information between
hospital and community practitioners and improve
communication between patients and their health
professionals.14-16 HMRs can also increase patients’
understanding of and compliance with their medication
regimens and reduce medication-related problems.13
A model was developed to enhance post-discharge
medication management and involved a hospital liaison
pharmacist who supported GPs to refer patients for HMRs
in the immediate post-discharge period.14,15 During this
period, the GP referral rates were around 90% and issues
raised by the accredited pharmacists in HMR reports
resulted in positive clinical outcomes.16 However,
conducting timely post-discharge HMRs has proved
problematic. Two trials implementing this model resulted
in median times to conduct HMRs of 18 and 32 days
after hospital discharge.14,15 This delay could be
addressed if hospital staff bypassed community
practitioners and directly referred at-risk patients to
accredited pharmacists for medication reviews.
An aspect of the quality use of medicines is the
quality of the conduct of the HMRs and ensuing
reports.17,18 Feedback from focus groups has indicated
that GPs perceive the quality and content of HMR reports
to be variable.18 We sought to enhance the quality of
HMR reports by designing a referral form with
comorbidity–specific questions to guide accredited
pharmacists with the medication reviews and reports.
This study aimed to determine if hospital-initiated
medication reviews (HIMRs) can be implemented in a
more timely manner than HMRs; and to assess the impact
of a bespoke referral form listing comorbidity-specific
questions on the quality of reports.
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Figure 1. Flow of participants through the study (HIMR = hospital-initiated medication reviews).
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METHOD
This study was approved by the Royal Adelaide Hospital
Research Ethics Committee and conducted over two
months from 1 August 2007. Medical inpatients at the
640-bed adult teaching hospital were screened for
eligibility. Social, demographic and laboratory data were
collected from medical records and during interviews with
consenting patients. Inclusion criteria included: eligible
to have an HMR and/or with one or more risk factors for
medication misadventure.16 Exclusion criteria included:
severe cognitive impairment; alcohol abuse; discharge
to a residential aged-care facility; transfer to critical care
units; and/or receiving palliative care.
Study Design
A range of health professionals were consulted when
designing the referral forms to identify comorbidity–
specific questions for the accredited pharmacists to ask
during the reviews that would provide useful information
for the patient’s healthcare team. Eighteen referral forms
were designed to cover the most common comorbidities
seen in general medicine: asthma, atrial fibrillation,
cerebrovascular disease, chronic obstructive pulmonary
disease, chronic renal failure, congestive heart failure,
depression, diabetes, dyslipidaemia, falls, gastro-
oesophageal reflux disease, gout, hypertension,
ischaemic heart disease, obesity, osteoarthritis,
osteoporosis and peripheral vascular disease.
An Access database was used to generate a bespoke
referral form for each patient. The form included details
of the patient’s renal function, medications and questions
specific to the patient’s comorbidities. To illustrate, an
example of the questions generated for patients with
congestive heart failure is presented in the Appendix.
Accredited pharmacists in the hospital’s regional
health service area were invited to participate in the study
by e-mail and newsletter. Those who agreed to participate,
attended a workshop and were given an overview of the
project and information on how to use the referral form.
They were invited to give feedback on the referral forms
after using them to conduct their reviews.
The hospital liaison pharmacist bypassed the GP and
community pharmacist referral process by directly
referring eligible patients to accredited pharmacists for
medication reviews. After the HIMR, the patient’s GP
and community pharmacist were given copies of the
report to maintain their engagement in the medication
management process.
Issues Identified
Issues raised by accredited pharmacists in the HIMR
reports were categorised by a consultant pharmacologist
and an academic pharmacist as intervention/action,
information given or recommendation. Each issue was
also given a rank of clinical significance: negative (-1),
none (0), minor (1), significant (2), very significant (3),
potentially life-saving (4) (Table 1). The clinical ranking
tool has been used by researchers to determine the impact
of issues raised in medication review reports.16,17,19 The
tool has been validated by the Western Australian Clinical
Pharmacists Group using a consensus panel.20 We
determined inter-rater reliability for this approach among
independent multidisciplinary raters, however, the gamma
statistic only indicated fair to moderate agreement.19
Therefore, we used a consensus panel of raters with
access to comprehensive patient data who assessed the
clinical impact from a whole of patient perspective.
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Data and statistical analysis were performed using
Excel and Access and the Statistical Package for the Social
Sciences (version 15).
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RESULTS
Of the 129 eligible hospital inpatients identified, 71 met
the inclusion criteria and 53 gave consent. Eleven
patients did not complete the study, therefore, data on
36 patients who completed the process (six reports were
excluded as they were not received within the study
period) were analysed (Figure 1).
Characteristics of the participants are presented in
Table 2. The mean age was 75.3 years and 17 (47%)
patients were males. The median length of hospital stay
was seven days (range 4 to 51). The mean number of
comorbidities was 8.7 (± 3.7) with cardiovascular disease
(hypertension 78%; congestive heart failure 72%;
ischaemic heart disease 72%) the most common.
Timeliness and Receipt of Reports
The mean number of days from discharge to HIMR
interview was 11.6 ± 6.6 days. The average and median
times elapsing between the HIMR and receipt of the
report by the referring clinician was 7.5 ± 8.9 days and 4
(range 2 to 50) days, respectively.
Referral Form
Ten accredited pharmacists conducted 42 HIMRs. In 14
(42%) reports the accredited pharmacists either
overlooked the comorbidity-specific questions or
answered only some of them. In four (12%) reports, the
accredited pharmacists responded with yes/no answers
while in five (15%) reports the focus was mostly on the
questions. In 11 (32%) reports, the accredited pharmacists
answered all the questions and at the same time
implemented many actions and recommendations.
Clinical Impact
A total of 1442 issues were identified in the 36 reports
(mean 40 issues identified per report). Of these, 1204
(84%) issues were categorised as information given, 150
(10%) were actions and 88 (6%) were recommendations.
Frequency of the clinical significance for the issues
identified in the medication review reports and examples
of rankings assigned to the identified issues are
presented in Tables 3 and 4.
DISCUSSION
Timeliness of Reports
The average time to conduct HIMRs was 11.6 (± 6.6)
days, which was more timely than the post-discharge
HMRs reported in our two earlier studies (18 and 32 days)
that were conducted at the same hospital and included
patients with similar demographics.14,15 The risk of
medication-related problems is greatest in the 7 to 10
days after discharge from hospital and HIMRs conducted
in a timely manner can reduce medication misadventure
during this high-risk period.1 The time between the HIMR
interview and receipt of the report by the referring
clinician was variable. It was important that there was an
opportunity for community pharmacists to work with
patients to generate a medication management plan.
Variability in Reports
Although only ten accredited pharmacists undertook the
36 HIMRs and that they were all in receipt of similar
referral forms, significant variability was observed in the
content of the reports. Several accredited pharmacists
incorporated the comorbidity-specific questions in the
referral forms into their reports. Others used the usual
process and only addressed the questions in part or
with a yes/no answer. Factors contributing to the
reluctance to the full use of the referral form are those
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often cited as barriers to behavioural change in the
healthcare setting: unfamiliarity of the process, inertia of
previous practice and difficulties seeing relevance.21 A
resource based on the comorbidity-specific referral
questions is currently being developed for a trial by newly
accredited pharmacists.
Issues Identified
Forty issues per report were identified in the 36 HIMR
reports while Nguyen et al.16 identified 4.7 issues per
report from 21 HMR reports and Ponniah et al.19 identified
12.2 issues per report from 39 HMR reports for patients
with heart failure. The higher number of issues identified
per HIMR report in this study suggests that the referral
form led to the identification of more issues.
Categorisation of Issues
The majority of issues raised were classified as
information given (84%) followed by actions taken (10%)
and recommendations given (6%). There was an average
of 33.4 information issues per report identified, which
was much higher than the 3.5 information issues per report
identified by Nguyen et al.16 and 4 information issues
reported by Ponniah et al.19 An average of 4.2 pharmacists’
actions/interventions per report were identified, which
was more than the mean of 1.2 interventions and 2.6
actions/interventions identified in previous studies.16,19
These increases can be attributed to the use of the
bespoke referral form.
A mean of 2.4 recommendations were identified per
report, which is lower than the 3.1 recommendations per
report identified by Ponniah et al.19
Clinical Impact
Of the 1442 issues identified, 89% were classified as
having a minor clinical impact while 43% had a significant
impact. Issues were most frequently classified as having
minor impact (46%) and significant impact (36%). The
clinical impact was lower (7%) than reported by Nguyen
et al.16 where 42% of issues were classified as very
significant. This may be due to the fact that most of the
participating accredited pharmacists documented a broad
range of issues in their reports when using the referral
form, although the majority of issues were of lesser clinical
impact.
Although there is controversy regarding the value
of medication reviews, this study demonstrated that
HIMRs can reduce medication misadventure when
patients are most vulnerable.16,19,22 This study also
demonstrated that the use of a bespoke referral form can
result in increased actions/interventions by accredited
pharmacists during medication reviews.
Limitations
These findings are limited due to the small sample size of
patients and accredited pharmacists. Although the
timeliness of HIMRs and HMRs were compared when
conducted under similar conditions, this was not a
controlled trial. An economic evaluation was not
undertaken and the impact of interventions on patient
outcomes was not assessed. Also, the clinical impact of
issues raised was undertaken by two raters only.
CONCLUSION
Medication reviews can be facilitated in a more timely
manner at discharge when accredited pharmacists are
engaged by the hospital. Referral forms with comorbidity-
specific questions can broaden the issues identified
during the interviews. There was as associated positive
clinical impact of issues raised in the HIMR reports.
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